Abstract: Gastric cancer (GC) is one of the most common malignant tumors of the digestive system. Human epidermal growth factor receptor 2 (HER2) is an important therapeutic target in GC. In recent years, anti-HER2 agents have made significant breakthroughs in GC treatment, providing more options for patients. To better guide the rational, effective, and safe application of anti-HER2 therapy in clinical practice, the Gastric Cancer Committee of China Anti-Cancer Association assembled domestic experts in the field of GC. After multiple rounds of discussions, they systematically reviewed domestic and international evidence-based data and integrated it with clinical practices in China. As a result, they formulated the “Chinese expert consensus on anti-HER2 therapy for gastric cancer (2024 edition)” to address the use of anti-HER2 therapy in advanced and perioperative settings, conversion therapy, and key considerations during treatment. This consensus aimed to further standardize and guide the clinical practice of anti-HER2 therapy for GC.